Does antenatal magnesium sulphate given to women at risk of preterm birth between 30 and 34 weeks' gestation reduce the risk of death or cerebral palsy in their children? - a randomised controlled trial

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/GNT1022968

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Antenatal magnesium sulphate is recommended prior to preterm birth at less than 30 weeks’ gestation. Whether there are benefits at later gestations is uncertain. This study is assessing whether magnesium sulphate given to women at risk of very preterm birth between 30 to 34 weeks’ gestation increases the chance of their baby surviving without cerebral palsy.

Funded Activity Details

Start Date: 01-01-2012

End Date: 01-01-2017

Funding Scheme: Project Grants

Funding Amount: $1,978,760.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Paediatrics

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

cerebral palsy | child development | evidence-based clinical practice | neuroprotection | premature birth | randomised controlled trial (RCT)

Related Links